PTGX – Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc.PTGX
$55.69Name : Protagonist Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,451,777,536.00
EPSttm : 0.78
Protagonist Therapeutics, Inc.
$55.69
0.86%$0.475Float Short %
10.13
Margin Of Safety %
22
Put/Call OI Ratio
0.89
EPS Next Q Diff
-0.35
EPS Last/This Y
-6.01
EPS This/Next Y
0.45
Price
55.71
Target Price
68.42
Analyst Recom
1.17
Performance Q
12.64
Relative Volume
1.26
Beta
2.26
Ticker: PTGX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | PTGX | 50.19 | 0.77 | 0.08 | 7461 |
| 2025-06-03 | PTGX | 51.07 | 0.79 | 0.45 | 7463 |
| 2025-06-04 | PTGX | 51.5 | 0.80 | 22.26 | 7525 |
| 2025-06-05 | PTGX | 53.83 | 0.92 | 0.03 | 8064 |
| 2025-06-06 | PTGX | 54.42 | 0.90 | 0.04 | 8150 |
| 2025-06-09 | PTGX | 55.67 | 0.88 | 0.29 | 8271 |
| 2025-06-10 | PTGX | 56.4 | 0.88 | 1.43 | 8302 |
| 2025-06-11 | PTGX | 55.31 | 0.87 | 1.50 | 8321 |
| 2025-06-12 | PTGX | 56.38 | 0.88 | 0.11 | 8333 |
| 2025-06-13 | PTGX | 56.39 | 0.88 | 0.43 | 8332 |
| 2025-06-16 | PTGX | 54.67 | 0.88 | 0.52 | 8354 |
| 2025-06-17 | PTGX | 55.2 | 0.87 | 0.13 | 8388 |
| 2025-06-18 | PTGX | 54.16 | 0.86 | 0.28 | 8434 |
| 2025-06-20 | PTGX | 53.37 | 0.87 | 17.00 | 8575 |
| 2025-06-23 | PTGX | 53.4 | 0.87 | 5.59 | 8080 |
| 2025-06-24 | PTGX | 53.68 | 0.89 | 0.15 | 8226 |
| 2025-06-25 | PTGX | 54.5 | 0.89 | 0.70 | 8247 |
| 2025-06-26 | PTGX | 55.24 | 0.89 | 96.40 | 8303 |
| 2025-06-27 | PTGX | 55.68 | 0.89 | 0.01 | 8289 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | PTGX | 50.17 | -0.9 | - | -1.48 |
| 2025-06-03 | PTGX | 51.06 | -0.9 | - | -1.48 |
| 2025-06-04 | PTGX | 51.53 | -0.9 | - | -1.48 |
| 2025-06-05 | PTGX | 53.82 | -0.9 | - | -1.48 |
| 2025-06-06 | PTGX | 54.38 | -0.9 | - | -1.48 |
| 2025-06-09 | PTGX | 55.68 | -0.9 | - | -1.48 |
| 2025-06-10 | PTGX | 56.38 | -0.9 | - | -1.48 |
| 2025-06-11 | PTGX | 55.33 | -0.9 | - | -1.48 |
| 2025-06-12 | PTGX | 56.32 | -0.9 | - | -1.48 |
| 2025-06-13 | PTGX | 56.36 | -0.9 | - | -1.48 |
| 2025-06-16 | PTGX | 54.65 | -0.9 | - | -1.48 |
| 2025-06-17 | PTGX | 55.24 | -0.9 | - | -1.48 |
| 2025-06-18 | PTGX | 53.92 | -0.9 | - | -1.48 |
| 2025-06-20 | PTGX | 53.34 | 0.1 | - | -1.54 |
| 2025-06-23 | PTGX | 53.37 | 0.1 | - | -1.54 |
| 2025-06-24 | PTGX | 53.64 | 0.1 | - | -1.54 |
| 2025-06-25 | PTGX | 54.45 | 0.1 | - | -1.54 |
| 2025-06-26 | PTGX | 55.22 | 0.1 | - | -1.54 |
| 2025-06-27 | PTGX | 55.71 | 0.1 | - | -1.54 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | PTGX | -1.78 | -0.16 | 9.07 |
| 2025-06-03 | PTGX | -1.78 | -0.16 | 9.07 |
| 2025-06-04 | PTGX | -1.78 | -0.16 | 9.07 |
| 2025-06-05 | PTGX | -1.78 | -0.16 | 9.07 |
| 2025-06-06 | PTGX | -1.78 | -0.16 | 9.07 |
| 2025-06-09 | PTGX | -1.78 | -0.15 | 9.07 |
| 2025-06-11 | PTGX | -1.78 | -0.15 | 8.93 |
| 2025-06-12 | PTGX | -2.30 | -0.15 | 8.93 |
| 2025-06-13 | PTGX | -2.30 | -0.15 | 8.93 |
| 2025-06-16 | PTGX | -2.30 | -0.10 | 8.90 |
| 2025-06-17 | PTGX | -2.46 | -0.10 | 8.90 |
| 2025-06-18 | PTGX | -2.46 | -0.10 | 8.90 |
| 2025-06-19 | PTGX | -2.46 | -0.10 | 8.90 |
| 2025-06-20 | PTGX | -2.46 | -0.10 | 8.90 |
| 2025-06-24 | PTGX | -2.33 | -0.21 | 8.93 |
| 2025-06-25 | PTGX | -2.33 | -0.21 | 8.93 |
| 2025-06-26 | PTGX | -2.33 | -0.21 | 10.13 |
| 2025-06-27 | PTGX | -2.33 | -0.21 | 10.13 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.19
Avg. EPS Est. Current Quarter
-0.5
Avg. EPS Est. Next Quarter
-0.54
Insider Transactions
-2.33
Institutional Transactions
-0.21
Beta
2.26
Average Sales Estimate Current Quarter
8
Average Sales Estimate Next Quarter
8
Fair Value
67.79
Quality Score
58
Growth Score
62
Sentiment Score
79
Actual DrawDown %
8.1
Max Drawdown 5-Year %
-85.8
Target Price
68.42
P/E
73.21
Forward P/E
PEG
P/S
16.61
P/B
5.01
P/Free Cash Flow
10.29
EPS
0.76
Average EPS Est. Cur. Y
-1.54
EPS Next Y. (Est.)
-1.09
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
27.04
Relative Volume
1.26
Return on Equity vs Sector %
-15.8
Return on Equity vs Industry %
2.1
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.13
EBIT Estimation
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 124
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading